Greenwich LifeSciences (GLSI)
Runs a single Phase III trial for a peptide vaccine preventing HER2-positive breast cancer recurrence.
$17.51
After hours−0.02 (−0.11%)
At close$17.53(−10.01%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 11.61% | 1.70M shares | |
|---|---|---|---|
| 60 holders · as of Jun 30, 2026 | |||
| Insiders | 78.15% | 11.47M shares | |
| 4 holders · as of Jul 30, 2026 | |||
| Other | 10.24% | 1.50M shares | |
| remainder | |||
14.68M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
60 holders · 1.70M shares · 10 new positions · 33 increased · 15 reduced · 13 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 485.9K | 3.31% | +52.0K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 278.2K | 1.90% | −20.1K | Aug 13, 2026 |
| Geode Capital Management, LLC | 168.2K | 1.15% | +12.7K | Aug 12, 2026 |
| State Street Corp | 143.1K | 0.97% | +9.2K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 80.9K | 0.55% | +22.0K | Aug 13, 2026 |
| Northern Trust Corp | 80.2K | 0.55% | +5.1K | Aug 13, 2026 |
| Bank of New York Mellon Corp | 47.9K | 0.33% | +1.4K | Aug 6, 2026 |
| Vanguard Fiduciary Trust Co | 46.0K | 0.31% | +1.1K | Aug 13, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 28, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 1,500 | $13.59 | 5,610,702 |
| Jul 29, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 700 | $13.10 | 5,611,402 |
| Jul 27, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 1,500 | $13.62 | 5,609,202 |
| Jul 23, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 2,500 | $13.14 | 5,606,602 |
| Jul 24, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 1,100 | $12.88 | 5,607,702 |
| Jan 13, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 1,800 | $29.83 | 5,604,102 |
| Jan 12, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 2,900 | $27.54 | 5,602,302 |
| Dec 31, 2025 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 4,300 | $21.36 | 5,599,402 |
| Dec 30, 2025 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 2,900 | $21.73 | 5,595,102 |
| Dec 18, 2025 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 4,100 | $12.62 | 5,592,202 |
House and Senate disclosures
Not reported.